Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

As shares of Boston-based Vertex shot higher on the news of its non-opioid pill, Journavx, we took a look at investment in startups focused on pain management and treatment. Turns out there’s quite a ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...